CardioGenics Holdings (CardioGenics Holdings) ROCE % : 0.00% (As of Jan. 2016)

View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CardioGenics Holdings's annualized ROCE % for the quarter that ended in Jan. 2016 was 0.00%.

CardioGenics Holdings ROCE % Historical Data

The historical data trend for CardioGenics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings ROCE % Chart

CardioGenics Holdings Annual Data

Trend

Jul06

Jul07

Jul08

Oct09

Oct10

Oct11

Oct12

Oct13

Oct14

Oct15

ROCE %

Get a 7-Day Free Trial

-453.04

-7,194.44

CardioGenics Holdings Quarterly Data
	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13	Jan14	Apr14	Jul14	Oct14	Jan15	Apr15	Jul15	Oct15	Jan16
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

CardioGenics Holdings ROCE % Calculation

CardioGenics Holdings's annualized ROCE % for the fiscal year that ended in Oct. 2015 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Oct. 2015 )		(A: Oct. 2014 )		(A: Oct. 2015 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Oct. 2015 )		(A: Oct. 2014 )		(A: Oct. 2015 )
	=	-0.772	/	( ( (0.27 - 1.425)	+	(0.232 - 1.795) )	/ 2 )
	=	-0.772	/	( (-1.155	+	-1.563)	/ 2 )
	=	-0.772	/	-1.359
	=	56.81 %

CardioGenics Holdings's ROCE % of for the quarter that ended in Jan. 2016 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2016 )		(Q: Oct. 2015 )		(Q: Jan. 2016 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2016 )		(Q: Oct. 2015 )		(Q: Jan. 2016 )
	=	-0.804	/	( ( (0.232 - 1.795)	+	(0.558 - 2.345) )	/ 2 )
	=	-0.804	/	( ( -1.563	+	-1.787 )	/ 2 )
	=	-0.804	/	-1.675
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2016) EBIT data.

CardioGenics Holdings (OTCPK:CGNH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CardioGenics Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CardioGenics Holdings (CardioGenics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8

Website

http://www.cardiogenics.com

CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines